Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race

Executive Summary

The latest approvals for the Swiss major's PD-1/L1 inhibitor in both bladder and lung cancer will boost revenues of the drug which may be the last to market in Europe but not the least.

You may also be interested in...



Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.

Seattle Genetics Looking To Improve, Replace Standards Of Care

Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.

Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung

The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel